Related Experiment Videos
Pulmonary plasma cell granuloma improves with corticosteroid therapy
1Department of Internal Medicine, Toyama Rosai Hospital, Uozu, Japan.
Chest
|May 1, 1994
Summary
Pulmonary plasma cell granuloma, a rare postinflammatory pseudotumor, can be effectively treated with prednisolone. This middle-dosage corticosteroid therapy offers a non-cytotoxic option for managing these lung tumors.
Area of Science:
- Pulmonology
- Pathology
- Oncology
Background:
- Pulmonary plasma cell granuloma (PCG) is a rare benign lung tumor, often presenting as a postinflammatory pseudotumor.
- PCG can mimic malignant neoplasms, posing diagnostic challenges.
- Progression after respiratory infections has been noted in some PCG cases.
Observation:
- Two male patients, aged 48 and 32, presented with hemoptysis and radiographic evidence of lung masses.
- Transbronchial biopsies confirmed PCG, characterized by plasma cell proliferation and inflammatory infiltrate, excluding malignancy and tuberculosis.
- The observed PCG cases showed progression following respiratory infectious disease.
Findings:
- Systemic treatment with prednisolone (30 mg/d) was initiated due to surgical limitations and potential for relapse.
- Complete resolution of pulmonary lesions was observed within 2-4 weeks of prednisolone therapy.
- No recurrence was noted during the follow-up period, indicating treatment efficacy.
Implications:
- Middle-dose corticosteroid therapy with prednisolone is a viable, non-cytotoxic treatment for pulmonary plasma cell granuloma.
- This approach is particularly beneficial for multifocal, unresectable, or relapsing cases of PCG.
- Effective management of PCG with corticosteroids may prevent complications associated with surgical intervention.